November 2016
Appointment of Keith D. Robertson Vice-President of the Cancer Epigenetics Society
The Cancer Epigenetics Society officially appoints Dr. Keith Robertson, Officer at the Cancer Epigenetics Society and Professor of Molecular Pharmacology & Experimental Therapeutics at Mayo Clinic, Rochester (MN, USA), Vice-President of the Cancer Epigenetics Society. Keith [...]
Arid1a: a fertile target in the parched anticancer drug landscape
Recent work from several labs have shown ARID1A, the helicase/ATPase-containing SWI/SNF chromatin-remodeling factor, to be mutated in several cancers, most notably in ovarian cancer (some 50% of ovarian clear-cell carcinoma). Other cancers in which ARID1A was [...]
Cancer Epigenetics Society announces first partnership with Mexico
The Cancer Epigenetics Society enters into a partnership with the Mexican Society of Epigenetics and Regenerative Medicine, thus marking the beginning of a program of collaborations between the Cancer Epigenetics Society and research institutions and [...]
Cancer Epigenetics Database, Experimental section: KDMi are in!
The experimental section of the Cancer Epigenetics Drug Database has been expanded to now include a fourth class of epigenetics-targeting drugs: the inhibitors of histone (lysine) demethylases or KDMi. This database currently includes data on [...]
Appointment of Susan J. Clark Editor at CE
The Cancer Epigenetics Society officially appoints Dr. Susan J. Clark, Professor at University of New South Wales Faculty of Medicine in Sidney, Australia, Editor at Cancer Epigenetics (CE) journal series. Dr. Clark is also Group Leader of [...]
August 2016
Update on the Cancer Epigenetics Database, Experimental section
We at the Cancer Epigenetics Society have lately focused our efforts on expanding the experimental datasets of the Cancer Epigenetics Drug Database with emphasis on three large classes of epigenetics-targeting drugs. These are the inhibitors [...]